Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial"
- PMID: 32453693
- PMCID: PMC7250695
- DOI: 10.2450/2020.0116-20
Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial"
Conflict of interest statement
The Authors declare no conflicts of interest.
Comment on
-
Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial.Blood Transfus. 2020 May;18(3):237-238. doi: 10.2450/2020.0109-20. Blood Transfus. 2020. PMID: 32453692 Free PMC article. No abstract available.
References
-
- World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected. Interim guidance 28 January 2020. [Accessed on 27/04/2020]. Accessible at: https://www.who.int/docs/defaultsource/coronaviruse/clinical-management-....
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources